# Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12232731</article-id><article-id pub-id-type="pmid">40619376</article-id>
<article-id pub-id-type="publisher-id">4234</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04234-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Xu</surname><given-names>Qiang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhao</surname><given-names>Xue</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Xianze</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Ruizhe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Yuejuan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Tao</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Heshui</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>He</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Yuping</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Mingjun</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Chuntao</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Deliang</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xiaojie</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Tongsen</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Yin</surname><given-names>Xiaoyu</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yili</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiaobing</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhihua</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Rufu</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xue</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Huan</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Quanren</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Han</surname><given-names>Xiaohong</given-names></name><address><email>hanxiaohong@pumch.cn</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wu</surname><given-names>Wenming</given-names></name><address><email>doctorwuu@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04jztag35</institution-id><institution-id institution-id-type="GRID">grid.413106.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9889 6335</institution-id><institution>General Surgery Department, Dongcheng District, </institution><institution>Peking Union Medical College Hospital, </institution></institution-wrap>No. 1 Shuaifuyuan, Beijing, 100730 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04jztag35</institution-id><institution-id institution-id-type="GRID">grid.413106.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9889 6335</institution-id><institution>Clinical Pharmacology Research Centre, Dongcheng District, </institution><institution>Peking Union Medical College Hospital, </institution></institution-wrap>No. 1 Shuaifuyuan, Beijing, 100730 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04jztag35</institution-id><institution-id institution-id-type="GRID">grid.413106.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9889 6335</institution-id><institution>Department of Medical Oncology, </institution><institution>Peking Union Medical College Hospital, </institution></institution-wrap>Beijing, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03k14e164</institution-id><institution-id institution-id-type="GRID">grid.417401.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 6507</institution-id><institution>Division of Gastrointestinal and Pancreatic Surgery, </institution><institution>Zhejiang Provincial People&#x02019;s Hospital, </institution></institution-wrap>Hangzhou, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00p991c53</institution-id><institution-id institution-id-type="GRID">grid.33199.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 7223</institution-id><institution>Pancreatic Surgery, </institution><institution>Union Hospital Tongji Medical College, Huazhong University of Science and Technology, </institution></institution-wrap>Wuhan, China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05jb9pq57</institution-id><institution-id institution-id-type="GRID">grid.410587.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 6479 2668</institution-id><institution>Second Ward of Internal Medicine Digestive Disease, </institution><institution>Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, </institution></institution-wrap>Jinan, China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05jb9pq57</institution-id><institution-id institution-id-type="GRID">grid.410587.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 6479 2668</institution-id><institution>Phase I Clinical Research Center, </institution><institution>Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, </institution></institution-wrap>Jinan, China </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/047aw1y82</institution-id><institution-id institution-id-type="GRID">grid.452696.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 7533 3408</institution-id><institution>Department of Oncology, </institution><institution>The Second Affiliated Hospital of Anhui Medical University, </institution></institution-wrap>Hefei, China </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0152hn881</institution-id><institution-id institution-id-type="GRID">grid.411918.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 6427</institution-id><institution>Pancreatic Surgery, </institution><institution>Tianjin Medical University Cancer Institute &#x00026; Hospital, </institution></institution-wrap>Tianjin, China </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05201qm87</institution-id><institution-id institution-id-type="GRID">grid.411405.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 8861</institution-id><institution>Pancreatic Surgery, </institution><institution>Huashan Hospital, Fudan University, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05201qm87</institution-id><institution-id institution-id-type="GRID">grid.411405.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 8861</institution-id><institution>Phase I Clinical Research Laboratory, </institution><institution>Huashan Hospital, Fudan University, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01f77gp95</institution-id><institution-id institution-id-type="GRID">grid.412651.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 3502</institution-id><institution>Phase I, Clinical Research Laboratory, </institution><institution>Harbin Medical University Cancer Hospital, </institution></institution-wrap>Harbin, China </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/037p24858</institution-id><institution-id institution-id-type="GRID">grid.412615.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1803 6239</institution-id><institution>Department of Pancreatobiliary Surgery, </institution><institution>The First Affiliated Hospital, Sun Yat-Sen University, </institution></institution-wrap>Guangzhou, China </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/037p24858</institution-id><institution-id institution-id-type="GRID">grid.412615.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1803 6239</institution-id><institution>Phase I Clinical Trial Center, </institution><institution>The First Affiliated Hospital, Sun Yat-Sen University, </institution></institution-wrap>Guangzhou, China </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ypx8c21</institution-id><institution-id institution-id-type="GRID">grid.207374.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2189 3846</institution-id><institution>Department of Oncology, </institution><institution>The Affiliated Cancer Hospital, Zhengzhou University, </institution></institution-wrap>Zhengzhou, China </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01px77p81</institution-id><institution-id institution-id-type="GRID">grid.412536.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1791 7851</institution-id><institution>Department of Oncology, </institution><institution>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, </institution></institution-wrap>Guangzhou, China </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/045kpgw45</institution-id><institution-id institution-id-type="GRID">grid.413405.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0686</institution-id><institution>Pancreatic Center, </institution><institution>Guangdong Provincial People&#x02019;s Hospital, </institution></institution-wrap>Guangzhou, China </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ayvvz32</institution-id><institution-id institution-id-type="GRID">grid.497067.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 4902 6885</institution-id><institution>Jiangsu Hengrui Pharmaceuticals Co., Ltd, </institution></institution-wrap>Shanghai, China </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>402</elocation-id><history><date date-type="received"><day>31</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>6</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">This study assessed the safety, preliminary antitumor activity, and pharmacokinetics of HR070803 (a novel liposomal irinotecan) in combination with 5-FU/LV and oxaliplatin for treatment-naive patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).</p></sec><sec><title>Methods</title><p id="Par2">This multicenter, open-label, single-arm, dose-escalation phase 1 study recruited treatment-naive patients aged 18&#x02013;70 years with unresectable locally advanced or metastatic PDAC. Treatment doses were escalated from 40/60 (HR070803 40 mg/m<sup>2</sup> plus 5-FU/LV and oxaliplatin 60 mg/m<sup>2</sup>) to 60/60 and 60/85. The primary endpoints were maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D). Secondary endpoints included safety, preliminary antitumor activity, and pharmacokinetics.</p></sec><sec><title>Results</title><p id="Par3">A total of 41 patients were enrolled, including 6, 17, and 18 patients in the 40/60, 60/60, and 60/85 group, respectively. Only one patient in the 60/60 group experienced dose-limiting toxicities of grade 3 increased alanine aminotransferase and grade 3 increased aspartate aminotransferase, and the MTD was not reached. Adverse events of grade&#x02009;&#x02265;&#x02009;3 were reported in 31 (75.6%) patients, with the most common being decreased neutrophil count and increased gamma-glutamyltransferase. No treatment discontinuation occurred owing to adverse events, and there were no treatment-related deaths. The overall response (complete or partial response) rate was 29.3% in the total population. Pharmacokinetic results demonstrated prolonged circulation and slow release of free irinotecan.</p></sec><sec><title>Conclusions</title><p id="Par4">HR070803 plus 5-FU/LV and oxaliplatin demonstrated an acceptable toxicity, good antitumor activity, and favorable pharmacokinetic profile as a first-line treatment for patients with unresectable locally advanced or metastatic PDAC. Based on the comprehensive data obtained during the dose escalation and dose expansion stages, HR070803 60 mg/m<sup>2</sup> plus 5-FU/LV and oxaliplatin 85 mg/m<sup>2</sup> was chosen as the RP2D.</p></sec><sec><title>Trial registration</title><p id="Par5">Clinical trials.gov NCT04796948; registered March 15, 2021.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04234-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HR070803</kwd><kwd>liposomal irinotecan</kwd><kwd>untreated metastatic PDAC</kwd><kwd>phase 1 trial</kwd><kwd>RP2D</kwd></kwd-group><funding-group><award-group><funding-source><institution>Jiangsu Hengrui Pharmaceuticals Co., Ltd.</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par21">Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. For those diagnosed with metastatic disease, chemotherapy remains the principal treatment while the 5-year survival rate is only about 3% [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. FOLFIRINOX (combination of irinotecan, 5-fluorouracil [5-FU], leucovorin [LV], and oxaliplatin) is recommended as one of the first-line regimens by most guidelines [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Although the objective response rate of FOLFIRINOX may reach up to 31.6%, its application is limited by a high frequency of adverse events such as neutropenia, febrile neutropenia, diarrhea, and neuropathy [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par22">Irinotecan has been widely used in a variety of cancers, and SN-38 is the active metabolite [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. Liposomal irinotecan, which employed liposome encapsulation to maintain the concentration of irinotecan and SN-38 within tumor, was developed to promote drug delivery, reduce drug-related toxicities, and enhance anti-tumor efficacy [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Based on the NAPOLI-1 trial [<xref ref-type="bibr" rid="CR16">16</xref>], liposomal irinotecan (Onivyde&#x000ae;) in combination with 5-FU/LV has been approved for mPDAC following progression with gemcitabine-based therapy. Furthermore, the NAPOLI-3 trial demonstrated that the NALIRIFOX (liposomal irinotecan plus 5-FU/LV and oxaliplatin) exhibited significant improvements in overall survival and progression-free survival compared to nab-paclitaxel plus gemcitabine in patients with mPDAC, leading to its approval for mPDAC in the first-line treatment setting [<xref ref-type="bibr" rid="CR17">17</xref>]. However, the high mortality rate and poor prognosis associated with mPDAC underscore the need for novel agents with enhanced antitumor activity and low toxicity in addressing this unmet medical requirement for the patient population.</p><p id="Par23">HR070803, a novel liposomal irinotecan, utilizes a new nano-liposomal formulation incorporating surface-modified PEG-phospholipids with a particle size of approximately 80&#x02013;90 nM, has been developed for treating tumor since 2008. This formulation effectively shields the recognition and uptake by the reticuloendothelial system, ensuring high drug loading and stability [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Nano-liposomal formulation could enhance the permeability and retention effect of the drug, prolong drug exposure time in tumor tissue, and facilitate targeted delivery to tumor tissues [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Additionally, this formula has the potential to improve the therapeutic index of irinotecan by reducing the maximum plasma concentration (C<sub>max</sub>), thereby mitigating dose-related side effects [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. A randomized phase 3 study demonstrated that HR070803 (56.5 mg/m<sup>2</sup>) in combination with 5-FU/LV significantly improved the median overall survival compared to placebo in combination with 5-FU/LV, and this combination has been approved for use in locally advanced or metastatic pancreatic cancer following gemcitabine therapy failure in China [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par24">Here, we reported results from a multicenter, open-label, phase 1, dose-escalation and expansion study conducted to assess the safety, preliminary antitumor activity, and pharmacokinetics of HR070803 in combination with 5-FU/LV and oxaliplatin in treatment-naive patients with unresectable locally advanced or metastatic PDAC.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients</title><p id="Par25">Eligible participants were aged 18&#x02013;70 years with histologically or cytologically confirmed unresectable locally advanced or metastatic PDAC, had not received systemic antitumor treatment, had at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had adequate hematological, hepatic, renal, and cardiac function and a life expectancy of&#x02009;&#x02265;&#x02009;3 months. Patients who had received the last dose of adjuvant chemotherapy&#x02009;&#x0003e;&#x02009;12 months before screening and who had recovered from the toxicities of adjuvant therapy (grade&#x02009;&#x02264;&#x02009;1) were eligible. Key exclusion criteria included pancreatic cancers originating from non-pancreatic ductal epithelium, known central nervous system metastasis, and harboring homozygous mutations in the UGT1A1*28/*6 gene.</p></sec><sec id="Sec4"><title>Study design and procedures</title><p id="Par26">This multicenter, open-label, single-arm, phase 1 study (NCT04796948) was conducted in 12 sites in China (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) and consisted of a dose escalation stage and a dose expansion stage.</p><p id="Par27">In the dose escalation stage, a traditional "3&#x02009;+&#x02009;3" design was implemented and the dose-escalation scheme was designed as below: 40/60 group, HR070803 40 mg/m<sup>2</sup> (by free-base, the same below) plus 5-FU/LV and oxaliplatin 60 mg/m<sup>2</sup>; 60/60 group, HR070803 60 mg/m<sup>2</sup> plus 5-FU/LV and oxaliplatin 60 mg/m<sup>2</sup>; and 60/85 group, HR070803 60 mg/m<sup>2</sup> plus 5-FU/LV and oxaliplatin 85 mg/m<sup>2</sup>. The starting dose, dosing frequency, and maximum dose of HR070803 and oxaliplatin were determined based on animal toxicity studies and a phase 1b clinical trial of HR070803 (data on file, Hengrui), as well as the results of a similar drug, FOLFIRINOX, in the treatment of solid tumors [<xref ref-type="bibr" rid="CR24">24</xref>]. Patients were administered via intravenous infusion with the order as follows: oxaliplatin over 2 h followed by HR070803 over 90 (&#x000b1;&#x02009;5) minutes, then, fixed dose of LV (400 mg/m<sup>2</sup> in all cohorts) over 30 min followed by 5-FU (2400 mg/m<sup>2</sup> in all cohorts) over 46&#x02013;48&#x000a0;h every 2&#x000a0;weeks (q2w), on days 1 and 15 of each 4-week cycle.</p><p id="Par28">The following adverse events that occurred during cycle 1 in the dose escalation stage and were related to any of the treatment components were considered as dose-limiting toxicity: grade 3 or 4 non-hematological toxicity (except for nausea, vomiting, or diarrhea without treatment); grade 4 neutropenia lasting for&#x02009;&#x02265;&#x02009;5 days or febrile neutropenia; grade 3 thrombocytopenia with bleeding or grade 4 thrombocytopenia; grade 4 anemia; or any treatment-related toxicity leading to dose delay for&#x02009;&#x02265;&#x02009;15 days. If dose-limiting toxicities were experienced by&#x02009;&#x02265;&#x02009;2 patients in 40/60 group, dose de-escalation would occur to a lower dose of HR070803 (i.e. 30 mg/m<sup>2</sup>). If no dose-limiting toxicity was observed in the 60/85 group, an additional dose-escalation cohort could be added following the recommendation of the safety monitor committee (SMC). The maximum tolerated dose was defined as the HR070803 dose below which dose-limiting toxicity occurred in&#x02009;&#x02265;&#x02009;2 patients among the initially enrolled 3 patients or&#x02009;&#x02265;&#x02009;2 patients among the initially enrolled 6 patients in a cohort experienced a dose-limiting toxicity during days 1 to 28 in the first treatment cycle.</p><p id="Par29">Following the completion of the dose escalation stage, the dose expansion stage would be initiated based on the recommendations of the SMC to recruit additional participants to further evaluate the safety, pharmacokinetics, and preliminary efficacy. The treatment schedule and recommended dose level in the dose expansion stage were based on a thorough review and evaluation of all available data from the dose escalation stage by the SMC. The recommended phase 2 dose (RP2D) was subsequently decided by the SMC based on the comprehensive data obtained during the dose escalation and dose expansion stages, including the safety and tolerability, pharmacokinetics, and preliminary antitumor efficacy.</p><p id="Par30">The protocol and all amendments were approved by the ethics committee of each study center. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written, informed consent.</p></sec><sec id="Sec5"><title>Assessments</title><p id="Par31">Adverse events were monitored from treatment initiation to 28 days after the last dose and were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. Tumor response was evaluated every 8 weeks (&#x000b1;&#x02009;7 days) after the first treatment using computed tomography or magnetic resonance imaging according to RECIST v1.1, until progression disease, new antitumor therapy initiation, withdrawal of consent, lost follow-up or death, whichever occurred first. Complete or partial responses were required to be confirmed&#x02009;&#x02265;&#x02009;4 weeks after the first documentation.</p><p id="Par32">For pharmacokinetic assessment, blood samples (4 mL) were collected from each patient in the dose escalation and dose expansion cohorts at 12 timepoints (pre-dose, 1.5 h, 2 h, 4 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, and 120 h) after the first dose of HR070803 infusion in cycle 1. Plasma concentrations of total irinotecan, free irinotecan, and SN-38 were quantitated by validated liquid chromatography-tandem mass spectrometry analytical methods.</p></sec><sec id="Sec6"><title>Outcomes</title><p id="Par33">The primary endpoints were to explore the maximum tolerated dose and the RP2D. Secondary endpoints included: safety, objective response rate, disease control rate, duration of response, progression-free survival, overall survival, and pharmacokinetics. Pharmacokinetic parameters included: C<sub>max</sub>, time to C<sub>max</sub> (T<sub>max</sub>), the area under the plasma concentration-time curve (AUC<sub>last</sub> and AUC<sub>inf</sub>), half-life of drug elimination (t<sub>1/2</sub>), clearance (CL), and the volume of distribution (V<sub>z</sub>).</p></sec><sec id="Sec7"><title>Statistical analyses</title><p id="Par34">No formal hypothesis testing was implemented in this study. For dose escalation stage, the number of patients enrolled was dependent on the actual number of dose-limiting toxicities observed. A total of sample size of 40&#x02013;52 patients was estimated for this study.</p><p id="Par35">Safety was assessed in the safety set, which included all patients who received at least one administration with at least one post-baseline safety record. Efficacy was analyzed in the full analysis set, where all enrolled patients with at least one administration were included. Plasma concentrations and pharmacokinetic parameters were analyzed in patients who received at least one administration and had at least one post-baseline evaluable pharmacokinetic data. The median progression-free survival, overall survival, and duration of response were analyzed using the Kaplan-Meier method with 95% confidence intervals (CIs) calculated using Brookmeyer-Crowley method. Clopper-Pearson method was utilized to calculate 95% CIs for objective response rate and disease control rate. Baseline characteristics, toxicities, and certain pharmacokinetic parameters were summarized descriptively. Continuous variables were summarized as mean (standard deviation [SD]) or median (interquartile range [IQR] or range), while categorical variables were described by frequency (percentage, %). The plasma concentration versus time profiles were plotted. Non-compartment model (Phoenix WinNonlin v8.1 or higher, Certara, LP, Princeton, NJ, USA) was employed to calculate certain pharmacokinetic parameters. All the statistical analyses were performed using SAS version 9.4.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Patients and baseline characteristics</title><p id="Par36">Between April 8, 2021 and November 27, 2022, 41 patients were enrolled in the dose escalation (<italic>n</italic>&#x02009;=&#x02009;15) and the dose expansion group (<italic>n</italic>&#x02009;=&#x02009;26) from 12 sites in China. In the dose escalation stage, there were 6 patients enrolled in the 40/60 group, 6 in the 60/60 group, and 3 in the 60/85 group. In the dose expansion stage, 11 patients were enrolled in the 60/60 group and 15 were in the 60/85 group (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The median age of the study group was 57 years and 73.2% of them were male. Five (12.2%) patients were diagnosed as stage III and 36 (87.8%) patients were diagnosed as stage IV. For patients with metastatic diseases, liver (<italic>n</italic>&#x02009;=&#x02009;30, 73.2%) was the most frequent metastatic site and 24 (58.5%) patients have more than 2 metastases (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). As of the data cutoff on June 28, 2024, the median treatment duration was 3.6 (IQR 0.1&#x02013;9.0) months in 40/60 group, 3.4 (IQR 1.0&#x02013;7.0) months in 60/60 group, and 3.4 (IQR 1.6&#x02013;4.6) months in 60/85 group; the median follow-up duration was 21.7 (IQR 21.2&#x02013;23.4) months. All patients discontinued the treatment with radiographical progression being the primary reason (<italic>n</italic>&#x02009;=&#x02009;25, 61.0%), and 29 (70.7%) patients received post-discontinuation systemic antitumor therapy (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Patient disposition. Following the evaluation of the tolerability and antitumor activity in the first two stages, we decided to expand the number of patients in the dose expansion stage, and no further enrollment of patients in the clinical expansion stage was conducted. *Among the first 3 patients enrolled in the 40/60 dose group, one patient had an adverse event (hepatic function abnormality of grade 3, a suspected dose-limiting toxicity) that was initially considered a dose-limiting toxicity. Following the &#x0201c;3&#x02009;+&#x02009;3&#x0201d; rule, we subsequently enrolled another 3 patients in the 40/60 group. However, upon follow-up assessment, it was found that hepatic function abnormality of grade 3 was caused by the obstruction of the biliary tract induced by pancreatic tumor, and was not a dose-limiting toxicity related to the treatment. Therefore, there was no occurrence of dose-limiting toxicity in the 40/60 group. The dose-limiting toxicity analysis set included all patients who have been enrolled in the dose escalation stage, have received at least one dose of the study drug, and have completed dose-limiting toxicity assessment. There were two patients enrolled in the 40/60 group during the dose-escalation stage did not meet the criteria of the dose-limiting toxicity analysis set. One patient had biliary stricture due to tumor-related reasons, which made it impossible to complete the dose-limiting toxicity observation. The other patient voluntarily requested to terminate the study treatment and thus did not complete the dose-limiting toxicity observation. Abbreviation: DLT, dose-limiting toxicity</p></caption><graphic xlink:href="12916_2025_4234_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><bold>40/60 group (N&#x02009;=&#x02009;6)</bold></th><th align="left"><bold>60/60 group (N&#x02009;=&#x02009;17)</bold></th><th align="left"><bold>60/85 group (N&#x02009;=&#x02009;18)</bold></th><th align="left"><bold>Total (N&#x02009;=&#x02009;41)</bold></th></tr></thead><tbody><tr><td align="left">Age, years</td><td align="left">56.0 (38&#x02013;66)</td><td align="left">57.0 (27&#x02013;68)</td><td align="left">58.0 (36&#x02013;67)</td><td align="left">57.0 (27&#x02013;68)</td></tr><tr><td align="left">Male</td><td align="left">5 (83.3)</td><td align="left">12 (70.6)</td><td align="left">13 (72.2)</td><td align="left">30 (73.2)</td></tr><tr><td align="left" colspan="5">ECOG performance score</td></tr><tr><td align="left">&#x02003;0</td><td align="left">1 (16.7)</td><td align="left">5 (29.4)</td><td align="left">4 (22.2)</td><td align="left">10 (24.4)</td></tr><tr><td align="left">&#x02003;1</td><td align="left">5 (83.3)</td><td align="left">12 (70.6)</td><td align="left">14 (77.8)</td><td align="left">31 (75.6)</td></tr><tr><td align="left" colspan="5">Disease stage at initial diagnosis</td></tr><tr><td align="left">&#x02003;III</td><td align="left">0</td><td align="left">1 (5.9)</td><td align="left">4 (22.2)</td><td align="left">5 (12.2)</td></tr><tr><td align="left">&#x02003;IV</td><td align="left">6 (100)</td><td align="left">16 (94.1)</td><td align="left">14 (77.8)</td><td align="left">36 (87.8)</td></tr><tr><td align="left" colspan="5">Pancreatic tumor location</td></tr><tr><td align="left">&#x02003;Head</td><td align="left">1 (16.7)</td><td align="left">5 (29.4)</td><td align="left">8 (44.4)</td><td align="left">14 (34.1)</td></tr><tr><td align="left">&#x02003;Other</td><td align="left">5 (83.3)</td><td align="left">12 (70.6)</td><td align="left">10 (55.6)</td><td align="left">27 (65.9)</td></tr><tr><td align="left" colspan="5">Number of sites with metastasis</td></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;2</td><td align="left">2 (33.3)</td><td align="left">5 (29.4)</td><td align="left">8 (44.4)</td><td align="left">15 (36.6)</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;2</td><td align="left">4 (66.7)</td><td align="left">11 (64.7)</td><td align="left">9 (50.0)</td><td align="left">24 (58.5)</td></tr><tr><td align="left" colspan="5">Site of metastases</td></tr><tr><td align="left">&#x02003;Liver</td><td align="left">6 (100.0)</td><td align="left">13 (76.5)</td><td align="left">11 (61.1)</td><td align="left">30 (73.2)</td></tr><tr><td align="left">&#x02003;Lung</td><td align="left">1 (16.7)</td><td align="left">2 (11.8)</td><td align="left">2 (11.1)</td><td align="left">5 (12.2)</td></tr><tr><td align="left">&#x02003;Regional lymph node</td><td align="left">2 (33.3)</td><td align="left">5 (29.4)</td><td align="left">9 (50.0)</td><td align="left">16 (39.0)</td></tr><tr><td align="left">&#x02003;Distant lymph node</td><td align="left">0</td><td align="left">5 (29.4)</td><td align="left">3 (16.7)</td><td align="left">8 (19.5)</td></tr><tr><td align="left">&#x02003;Peritoneum</td><td align="left">0</td><td align="left">0</td><td align="left">1 (5.6)</td><td align="left">1 (2.4)</td></tr><tr><td align="left">&#x02003;Other</td><td align="left">1 (16.7)</td><td align="left">4 (23.5)</td><td align="left">3 (16.7)</td><td align="left">8 (19.5)</td></tr><tr><td align="left">CA19-9, U/mL</td><td align="left">834.0 (2.0&#x02013;2483.0)</td><td align="left">177.0 (8.1&#x02013;20,481.5)</td><td align="left">980.0 (2.0&#x02013;12000.0)</td><td align="left">316.9 (2.0&#x02013;20481.5)</td></tr><tr><td align="left" colspan="5">UGT1A1*28 genotype</td></tr><tr><td align="left">&#x02003;TA6/7</td><td align="left">0</td><td align="left">3 (17.6)</td><td align="left">4 (22.2)</td><td align="left">7 (17.1)</td></tr><tr><td align="left">&#x02003;TA6/6</td><td align="left">6 (100)</td><td align="left">14 (82.4)</td><td align="left">14 (77.8)</td><td align="left">34 (82.9)</td></tr><tr><td align="left" colspan="5">UGT1A1*6 genotype</td></tr><tr><td align="left">&#x02003;G/G</td><td align="left">4 (66.7)</td><td align="left">12 (70.6)</td><td align="left">8 (44.4)</td><td align="left">24 (58.5)</td></tr><tr><td align="left">&#x02003;A/G</td><td align="left">2 (33.3)</td><td align="left">5 (29.4)</td><td align="left">10 (55.6)</td><td align="left">17 (41.5)</td></tr></tbody></table><table-wrap-foot><p>Data are median (range) or n (%). ECOG, Eastern Cooperative Oncology Group</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Tolerability and safety</title><p id="Par37">In the dose escalation stage, one patient in the 60/60 group experienced dose-limiting toxicities of grade 3 increased alanine aminotransferase and grade 3 increased aspartate aminotransferase, which recovered spontaneously without intervention. Therefore, the maximum tolerated dose was not reached.</p><p id="Par38">Safety was assessed in 41 patients, with all of them experiencing at least one adverse events (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The most frequently reported AEs included neutropenia (82.9%, 34/41), nausea (80.5%, 33/41), decreased white blood cell (70.7%, 29/41), and anaemia (70.7%, 29/41). Adverse events of grade&#x02009;&#x02265;&#x02009;3 were reported in 31 (75.6%) patients, with the most common ones being decreased neutrophil count (41.5%, 17/41), increased gamma-glutamyltransferase (19.5%, 8/41), white decreased blood cell count (14.6%, 6/41), and increased alanine aminotransferase (12.2%, 5/41). Treatment-related adverse events of grade&#x02009;&#x02265;&#x02009;3 were reported in 25 (61.0%) patients, and the most common ones were decreased neutrophil count (41.5%, 17/41), increased gamma-glutamyltransferase (19.5%, 8/41), and decreased white blood cell (14.6%, 6/41) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3). Serious adverse events occurred in 19 (46.3%) patients, and those in 8 patients (19.5%) were considered to be treatment-related (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S4). Dose reduction and treatment interruption of any treatment component owing to adverse event was reported in 8 (19.5%) patients and 25 (61.0%) patients, respectively. No treatment discontinuation occurred due to adverse events, and no deaths attributed to adverse events were deemed treatment-related.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Adverse events</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">40/60 group (N&#x02009;=&#x02009;6)</th><th align="left" colspan="2">60/60 group (N&#x02009;=&#x02009;17)</th><th align="left" colspan="2">60/85 group (N&#x02009;=&#x02009;18)</th><th align="left" colspan="2">Total (N&#x02009;=&#x02009;41)</th></tr><tr><th align="left">Any grade</th><th align="left">Grade 3&#x02013;5</th><th align="left">Any grade</th><th align="left">Grade 3&#x02013;5</th><th align="left">Any grade</th><th align="left">Grade 3&#x02013;5</th><th align="left">Any grade</th><th align="left">Grade 3&#x02013;5</th></tr></thead><tbody><tr><td align="left">Any</td><td align="left">6 (100)</td><td align="left">5 (83.3)</td><td align="left">17 (100)</td><td align="left">13 (76.5)</td><td align="left">18 (100)</td><td align="left">13 (72.2)</td><td align="left">41 (100)</td><td align="left">31 (75.6)</td></tr><tr><td align="left">Neutrophil count decreased</td><td align="left">3 (50.0)</td><td align="left">2 (33.3)</td><td align="left">16 (94.1)</td><td align="left">6 (35.3)</td><td align="left">15 (83.3)</td><td align="left">9 (50.0)</td><td align="left">34 (82.9)</td><td align="left">17 (41.5)</td></tr><tr><td align="left">Nausea</td><td align="left">6 (100)</td><td align="left">0</td><td align="left">13 (76.5)</td><td align="left">1 (5.9)</td><td align="left">14 (77.8)</td><td align="left">0</td><td align="left">33 (80.5)</td><td align="left">1 (2.4)</td></tr><tr><td align="left">White blood cell count decreased</td><td align="left">3 (50.0)</td><td align="left">1 (16.7)</td><td align="left">13 (76.5)</td><td align="left">1 (5.9)</td><td align="left">13 (72.2)</td><td align="left">4 (22.2)</td><td align="left">29 (70.7)</td><td align="left">6 (14.6)</td></tr><tr><td align="left">Anaemia</td><td align="left">1 (16.7)</td><td align="left">0</td><td align="left">13 (76.5)</td><td align="left">1 (5.9)</td><td align="left">15 (83.3)</td><td align="left">0</td><td align="left">29 (70.7)</td><td align="left">1 (2.4)</td></tr><tr><td align="left">Alanine aminotransferase increased</td><td align="left">4 (66.7)</td><td align="left">0</td><td align="left">9 (52.9)</td><td align="left">3 (17.6)</td><td align="left">12 (66.7)</td><td align="left">2 (11.1)</td><td align="left">25 (61.0)</td><td align="left">5 (12.2)</td></tr><tr><td align="left">Diarrhoea</td><td align="left">3 (50.0)</td><td align="left">0</td><td align="left">10 (58.8)</td><td align="left">1 (5.9)</td><td align="left">10 (55.6)</td><td align="left">0</td><td align="left">23 (56.1)</td><td align="left">1 (2.4)</td></tr><tr><td align="left">Aspartate aminotransferase increased</td><td align="left">3 (50.0)</td><td align="left">0</td><td align="left">9 (52.9)</td><td align="left">2 (11.8)</td><td align="left">10 (55.6)</td><td align="left">2 (11.1)</td><td align="left">22 (53.7)</td><td align="left">4 (9.8)</td></tr><tr><td align="left">Gamma-glutamyltransferase increased</td><td align="left">4 (66.7)</td><td align="left">1 (16.7)</td><td align="left">10 (58.8)</td><td align="left">2 (11.8)</td><td align="left">7 (38.9)</td><td align="left">5 (27.8)</td><td align="left">21 (51.2)</td><td align="left">8 (19.5)</td></tr><tr><td align="left">Platelet count decreased</td><td align="left">3 (50.0)</td><td align="left">0</td><td align="left">7 (41.2)</td><td align="left">0</td><td align="left">11 (61.1)</td><td align="left">0</td><td align="left">21 (51.2)</td><td align="left">0</td></tr><tr><td align="left">Decreased appetite</td><td align="left">2 (33.3)</td><td align="left">0</td><td align="left">8 (47.1)</td><td align="left">0</td><td align="left">8 (44.4)</td><td align="left">1 (5.6)</td><td align="left">18 (43.9)</td><td align="left">1 (2.4)</td></tr><tr><td align="left">Constipation</td><td align="left">3 (50.0)</td><td align="left">0</td><td align="left">7 (41.2)</td><td align="left">0</td><td align="left">7 (38.9)</td><td align="left">0</td><td align="left">17 (41.5)</td><td align="left">0</td></tr><tr><td align="left">Hyponatraemia</td><td align="left">1 (16.7)</td><td align="left">0</td><td align="left">5 (29.4)</td><td align="left">0</td><td align="left">10 (55.6)</td><td align="left">0</td><td align="left">16 (39.0)</td><td align="left">0</td></tr><tr><td align="left">Vomiting</td><td align="left">1 (16.7)</td><td align="left">0</td><td align="left">7 (41.2)</td><td align="left">0</td><td align="left">8 (44.4)</td><td align="left">0</td><td align="left">16 (39.0)</td><td align="left">0</td></tr><tr><td align="left">Hypoalbuminaemia</td><td align="left">0</td><td align="left">0</td><td align="left">8 (47.1)</td><td align="left">0</td><td align="left">7 (38.9)</td><td align="left">0</td><td align="left">15 (36.6)</td><td align="left">0</td></tr><tr><td align="left">Weight decreased</td><td align="left">1 (16.7)</td><td align="left">0</td><td align="left">5 (29.4)</td><td align="left">0</td><td align="left">9 (50.0)</td><td align="left">1 (5.6)</td><td align="left">15 (36.6)</td><td align="left">1 (2.4)</td></tr><tr><td align="left">Hypokalaemia</td><td align="left">0</td><td align="left">0</td><td align="left">5 (29.4)</td><td align="left">1 (5.9)</td><td align="left">9 (50.0)</td><td align="left">3 (16.7)</td><td align="left">14 (34.1)</td><td align="left">4 (9.8)</td></tr><tr><td align="left">Asthenia</td><td align="left">2 (33.3)</td><td align="left">0</td><td align="left">6 (35.3)</td><td align="left">1 (5.9)</td><td align="left">5 (27.8)</td><td align="left">0</td><td align="left">13 (31.7)</td><td align="left">1 (2.4)</td></tr><tr><td align="left">Abdominal pain</td><td align="left">3 (50.0)</td><td align="left">0</td><td align="left">7 (41.2)</td><td align="left">0</td><td align="left">2 (11.1)</td><td align="left">0</td><td align="left">12 (29.3)</td><td align="left">0</td></tr><tr><td align="left">Blood alkaline phosphatase increased</td><td align="left">0</td><td align="left">0</td><td align="left">5 (29.4)</td><td align="left">0</td><td align="left">6 (33.3)</td><td align="left">0</td><td align="left">11 (26.8)</td><td align="left">0</td></tr><tr><td align="left">COVID-19</td><td align="left">0</td><td align="left">0</td><td align="left">2 (11.8)</td><td align="left">0</td><td align="left">9 (50.0)</td><td align="left">0</td><td align="left">11 (26.8)</td><td align="left">0</td></tr><tr><td align="left">Pyrexia</td><td align="left">0</td><td align="left">0</td><td align="left">6 (35.3)</td><td align="left">0</td><td align="left">4 (22.2)</td><td align="left">0</td><td align="left">10 (24.4)</td><td align="left">0</td></tr><tr><td align="left">Hyperglycaemia</td><td align="left">0</td><td align="left">0</td><td align="left">6 (35.3)</td><td align="left">0</td><td align="left">3 (16.7)</td><td align="left">0</td><td align="left">9 (22.0)</td><td align="left">0</td></tr><tr><td align="left">Lymphocyte count decreased</td><td align="left">1 (16.7)</td><td align="left">1 (16.7)</td><td align="left">4 (23.5)</td><td align="left">0</td><td align="left">4 (22.2)</td><td align="left">2 (11.1)</td><td align="left">9 (22.0)</td><td align="left">3 (7.3)</td></tr></tbody></table><table-wrap-foot><p>Data are n (%). Adverse events of any grade occurring in more than 20% of total patients and adverse events of grade 3&#x02013;5 occurring in more than 5% of total patients were listed</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Antitumor activity</title><p id="Par39">All of the 41 patients were included in the full analysis set. The confirmed overall response (complete or partial response) was achieved in 10 (24.4%, 95% CI 12.4%&#x02013;40.3%) patients, including 2 (33.3%) patients from 40/60 group, 4 (23.5%) from 60/60 group, and 4 (22.2%) from 60/85 group (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S5). Disease control was achieved in 28 (68.3%, 95% CI 51.9%&#x02013;81.9%) patients. For patients who achieved complete or partial responses, the estimated median duration of response was 5.5 (95% CI 2.0&#x02013;13.2) months (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S1A). The tumor response and response duration for each patient are presented in the waterfall plot (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A) and swimmer plot (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B). As of the data cutoff, 28 (68.3%) of the 41 patients experienced PFS events. The median progression-free survival was 5.4 (95% CI 3.7&#x02013;7.2) months, and the 6-months progression-free survival rate was 41.4% (95% CI 24.5%&#x02013;57.5%) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S1B). Thirty-six (87.8%) death events occurred, and the median overall survival data was 10.3 (95% CI 8.2&#x02013;11.2) months (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S1C).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Tumor response. <bold>A</bold>&#x000a0;The best percentage change from baseline in target tumor lesion size. Each bar represents a patient. <bold>B</bold>&#x000a0;Duration of tumor response in the full analysis population. PR, partial response; SD, stable disease; PD, progression disease</p></caption><graphic xlink:href="12916_2025_4234_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec12"><title>Pharmacokinetics</title><p id="Par40">Thirty-eight patients were included for plasma drug concentration analysis and 37 were included for pharmacokinetic parameters analysis. After a single administration of HR070803, the peak plasma concentrations of total irinotecan, free irinotecan, and SN-38 in the 40/60, 60/60, and 60/85 groups were reached within 1.75&#x02013;1.98 h, 1.55&#x02013;24.11 h, and 12.00&#x02013;24.00 h, respectively. The exposure (C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>inf</sub>) of total irinotecan, free irinotecan, and SN-38 increased with an increasing administration dose, with level of free irinotecan exposure remarkable lower than that of the total irinotecan. The half-life of drug elimination of total irinotecan, free irinotecan, and SN-38 in the three groups was 14.49&#x02013;18.53 h, 21.79&#x02013;24.93 h, and 25.17&#x02013;31.49 h, respectively. The clearance rate of total irinotecan among different dosage groups remained relatively consistent, ranging from 56.0 to 77.4 mL/(h*m<sup>2</sup>). The plasma concentration-time profiles of total irinotecan, free irinotecan, and SN-38 by dose are presented in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, and pharmacokinetic parameters by dose are summarized in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Plasma concentration-time profiles of irinotecan and its metabolite SN-38. <bold>A</bold>&#x000a0;Total irinotecan. <bold>B</bold>&#x000a0;Free irinotecan. <bold>C</bold>&#x000a0;SN-38</p></caption><graphic xlink:href="12916_2025_4234_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Pharmacokinetic parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><bold>40/60 group</bold></th><th align="left"><bold>60/60 group</bold></th><th align="left"><bold>60/85 group</bold></th></tr></thead><tbody><tr><td align="left" colspan="4">Total irinotecan</td></tr><tr><td align="left">&#x02003;T<sub>max</sub>, h</td><td align="left">1.75 (1.50&#x02013;4.00)</td><td align="left">1.76 (1.47&#x02013;2.48)</td><td align="left">1.98 (1.47&#x02013;2.02)</td></tr><tr><td align="left">&#x02003;C<sub>max</sub>, ug/mL</td><td align="left">21.27 (3.08)</td><td align="left">36.78 (4.03)</td><td align="left">33.50 (7.43)</td></tr><tr><td align="left">&#x02003;AUC<sub>last</sub>, h*ug/mL</td><td align="left">709.13 (128.07)</td><td align="left">1112.49 (235.6)</td><td align="left">900.36 (358.51)</td></tr><tr><td align="left">&#x02003;AUC<sub>inf</sub>, h*ug/mL</td><td align="left">723.57 (133.27)</td><td align="left">1122.43 (240.72)</td><td align="left">909.52 (363.24)</td></tr><tr><td align="left">&#x02003;t<sub>1/2</sub>, h</td><td align="left">18.53 (4.45)</td><td align="left">14.49 (3.49)</td><td align="left">15.33 (3.45)</td></tr><tr><td align="left">&#x02003;CL, mL/(h*m<sup>2</sup>)</td><td align="left">57.17 (12.49)</td><td align="left">56.00 (13.29)</td><td align="left">77.44 (33.65)</td></tr><tr><td align="left">&#x02003;V<sub>z</sub>, mL/m<sup>2</sup></td><td align="left">1489.85 (289.03)</td><td align="left">1171.69 (395.98)</td><td align="left">1611.91 (487.50)</td></tr><tr><td align="left" colspan="4">Free irinotecan</td></tr><tr><td align="left">&#x02003;T<sub>max</sub>, h</td><td align="left">24.11 (12.00&#x02013;48.00)</td><td align="left">8.00 (1.47&#x02013;47.45)</td><td align="left">1.55 (1.47&#x02013;24.00)</td></tr><tr><td align="left">&#x02003;C<sub>max</sub>, ng/mL</td><td align="left">78.40 (8.44)</td><td align="left">151.94 (38.23)</td><td align="left">183.60 (56.82)</td></tr><tr><td align="left">&#x02003;AUC<sub>last</sub>, h*ng/mL</td><td align="left">5207.47 (902.17)</td><td align="left">8486.49 (2217.24)</td><td align="left">8005.41 (2121.53)</td></tr><tr><td align="left">&#x02003;AUC<sub>inf</sub>, h*ng/mL</td><td align="left">5619.02 (1078.98)</td><td align="left">8922.17 (2360.31)</td><td align="left">8365.61 (2108.39)</td></tr><tr><td align="left">&#x02003;t<sub>1/2</sub>, h</td><td align="left">24.93 (5.16)</td><td align="left">22.39 (4.03)</td><td align="left">21.79 (4.79)</td></tr><tr><td align="left" colspan="4">SN-38</td></tr><tr><td align="left">&#x02003;T<sub>max</sub>, h</td><td align="left">24.00 (11.93&#x02013;36.00)</td><td align="left">12.00 (2.02&#x02013;48.00)</td><td align="left">12.00 (3.98&#x02013;36.25)</td></tr><tr><td align="left">&#x02003;C<sub>max</sub>, ng/mL</td><td align="left">3.45 (0.76)</td><td align="left">6.20 (2.72)</td><td align="left">7.29 (4.11)</td></tr><tr><td align="left">&#x02003;AUC<sub>last</sub>, h*ng/mL</td><td align="left">231.18 (36.19)</td><td align="left">344.20 (117.00)</td><td align="left">344.16 (120.36)</td></tr><tr><td align="left">&#x02003;AUC<sub>inf</sub>, h*ng/mL</td><td align="left">260.47 (49.31)</td><td align="left">371.72 (124.89)</td><td align="left">377.01 (129.67)</td></tr><tr><td align="left">&#x02003;t<sub>1/2</sub>, h</td><td align="left">31.49 (8.85)</td><td align="left">25.17 (8.97)</td><td align="left">29.71 (11.37)</td></tr></tbody></table><table-wrap-foot><p>Data are median (range) or mean (SD)</p></table-wrap-foot></table-wrap></p><p id="Par41">The evaluation of dose proportionality of plasma exposure to irinotecan and SN-38 was conducted using a power model. The levels of C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>inf</sub> of total irinotecan, free irinotecan, and SN-38 in plasma between the 60/60 group and 60/85 group (both irinotecan 60 mg/m<sup>2</sup>) were not significantly different (P&#x02009;&#x0003e;&#x02009;0.05), suggesting that the 60/60 and 60/85 groups could be combined for analysis to indicate the dose of irinotecan at 60 mg/m<sup>2</sup>. The power model analysis showed that within the dose range of 40 to 60 mg/m<sup>2</sup>, the C<sub>max</sub> of total irinotecan, free irinotecan, and SN-38 increased slightly higher than proportionally with dose; the AUC<sub>last</sub> and AUC<sub>inf</sub> of total irinotecan and SN-38 increased slightly less than proportionally with dose; and the AUC<sub>last</sub> and AUC<sub>inf</sub> of free irinotecan increased in a dose-dependent manner (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S2).</p><p id="Par42">Based on the comprehensive data obtained during the dose escalation and dose expansion stages, including the safety and tolerability, pharmacokinetics, and preliminary antitumor efficacy, the SMC decided to select the highest dose in this study (HR070803 60 mg/m<sup>2</sup> plus 5-FU/LV and oxaliplatin 85 mg/m<sup>2</sup>) as the RP2D.</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par43">In this phase 1 trial, we assessed the safety, preliminary antitumor activity, and pharmacokinetics of HR070803, a novel nano-liposomal formulation of irinotecan, in combination with 5-FU/LV plus oxaliplatin in treatment-naive patients with unresectable locally advanced or metastatic PDAC. The safety profile indicated that this treatment regimen was well-tolerated, with one patient from the 60/60 group experiencing dose-limiting toxicities of grade 3 increased alanine aminotransferase and increased aspartate aminotransferase, which spontaneously recovered within 8 days without intervention. The maximum tolerated dose was not reached. Based on safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy, the SMC has decided to choose the highest dose in this study (HR070803 60 mg/m<sup>2</sup> by free-base plus 5-FU/LV and oxaliplatin 85 mg/m<sup>2</sup>) as the RP2D. Pharmacokinetic results demonstrated a slower and more stable release of free irinotecan and SN-38 compared with conventional non-liposomal irinotecan [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par44">The specificity of the most frequent adverse events was generally consistent with those expected for conventional non-liposomal irinotecan, and no new toxicity signals were identified [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. The slow-release nature of HR070803, owing to its nano-liposomal formula and distinctive preparation technology, helped maintain the peak concentrations of free irinotecan and SN-38 at lower and stable levels. This led to comparatively lower incidences of decreased neutrophil count (82.9% vs 54%&#x02013;96.9%), diarrhea (56.1% vs 72.4%&#x02013;88%), and cholinergic syndrome (2.4% vs 28.3%) compared to irinotecan hydrochloride [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. The adverse event profiles both in the total patients and the RP2D group (60/85) observed in the current trial were generally in line with that previously reported for liposome irinotecan [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Notably, no treatment discontinuations due to adverse events were observed, whereas the incidence of treatment discontinuation due to adverse events in the NAPOLI 3 study was 32% [<xref ref-type="bibr" rid="CR17">17</xref>]. However, cross-trial comparisons should be interpreted with caution due to the lack of head-to-head studies.</p><p id="Par45">The incidences of diarrhea at any grade were similar among the three groups, with only one case of grade&#x02009;&#x02265;&#x02009;3 diarrhea occurring in the 60/60 group. This suggests that the dose escalation of HR070803 from 40 to 60 mg/m<sup>2</sup> had little impact on the incidence of diarrhea. The incidence of grade&#x02009;&#x02265;&#x02009;3 decreased neutrophil count remained stable with escalation of HR070803 dose from 40 to 60 mg/m<sup>2</sup> but increased with oxaliplatin dose escalation from 60 to 85 mg/m<sup>2</sup>, indicating that it may be plausible to start with dose reduction of oxaliplatin when intolerable decreased neutrophil count occurs in subsequent phase 3 study. Oxaliplatin-containing regimens can potentially cause grade&#x02009;&#x02265;&#x02009;3 sensory neuropathy (9.0% of patients receiving FOLFIRINOX in the PRODIGE 4 study) [<xref ref-type="bibr" rid="CR6">6</xref>], but none was reported in our study. Therefore, in subsequent clinical studies with longer-term follow-up, it is necessary to continue monitoring whether the oxaliplatin in our combination strategy carries the risk of causing sensory neuropathy.</p><p id="Par46">During the study, a significant COVID-19 outbreak occurred from November 2022 to January 2023, leading to medication administration delays for 13 patients in our study, 12 patients experienced a cumulative delay of&#x02009;&#x02265;&#x02009;2 weeks. Notably, four patients had a cumulative delay in medication administration of&#x02009;&#x02265;&#x02009;21 days before their initial tumor assessment. Considering the rapid progression of pancreatic cancer, these medication delays may have led to an underestimation of antitumor activity of the study treatment. Despite the impact of the COVID-19 pandemic on the study, 26 (63.4%) of the 41 patients achieved a reduction in tumor lesion size from baseline, with a percentage change of reduction ranging from 0.8% to 72.1%.</p><p id="Par47">In terms of pharmacokinetics, the levels of free irinotecan exposure (AUC<sub>last</sub> and AUC<sub>inf</sub>) in the 60/60 and 60/85 groups were only 0.76%&#x02013;0.92% of the total irinotecan. Furthermore, when compared to free-form irinotecan [<xref ref-type="bibr" rid="CR26">26</xref>], the administration of HR070803 resulted in higher overall exposure (C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>inf</sub>) and a longer half-life of total irinotecan, as well as low C<sub>max</sub> and prolonged half-life of free irinotecan. These findings suggest that HR070803 demonstrates characteristics of prolonged circulation and a slow release of irinotecan.</p><p id="Par48">This study has several limitations. Firstly, the sample size was relatively small, which limited the precision of antitumor activity parameter estimates and made it infeasible to conduct subgroup analysis based on prognostic factors such as age, gender, disease stage, or biomarker status. Secondly, the study was also limited by its non-randomized design and the absence of a control group. Thirdly, due to the impact of the COVID-19 pandemic, the efficacy of the HR070803 combination regimen was underestimated. However, the primary significance of this study lies in the exploration of tolerable doses and the RP2D of this combination regimen in unresectable, locally advanced, or metastatic PDAC, and the efficacy results of this trial warrant further validation in a larger randomized study in this population.</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par49">In conclusion, HR070803 plus 5-FU/LV and oxaliplatin demonstrated a tolerable safety profile with regard to both hematological and non-hematological adverse events and exhibited good antitumor activity as a first-line treatment for patients with unresectable, locally advanced, or metastatic PDAC. The slow but prolonged stable release of irinotecan and SN-38 due to the nanoscale liposome encapsulation further supports its potential efficacy and tolerability. A large randomized controlled phase 3 study comparing this combination regimen with gemcitabine/nab-paclitaxel in this population is currently underway.</p></sec><sec id="Sec15" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4234_MOESM1_ESM.docx"><caption><p>Additional file 1: Figures S1-S2 and Tables S1-S5. Fig. S1. Kaplan-Meier curves of efficacy endpoints. (A) Duration of response. (B) Progression-free survival. (C) Overall survival. Fig. S2. Dose proportionality of plasma exposure of total irinotecan, free irinotecan, and SN-38. (A) Total irinotecan. (B) Free irinotecan. (C) SN-38. Table S1. Participating sites. Table S2. Subsequent post-discontinuation antitumor therapy. Table S3. Treatment-related adverse events. Table S4. Serious adverse events. Table S5. Antitumor activity.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>5-FU</term><def><p id="Par6">5-fluorouracil</p></def></def-item><def-item><term>AUC</term><def><p id="Par7">The area under the plasma concentration-time curve</p></def></def-item><def-item><term>CI</term><def><p id="Par8">Confidence interval</p></def></def-item><def-item><term>CL</term><def><p id="Par9">Clearance</p></def></def-item><def-item><term>C<sub>max</sub></term><def><p id="Par10">Maximum plasma concentration</p></def></def-item><def-item><term>LV</term><def><p id="Par11">Leucovorin</p></def></def-item><def-item><term>NCI-CTCAE</term><def><p id="Par12">National Cancer Institute Common Terminology Criteria for Adverse Events</p></def></def-item><def-item><term>PDAC</term><def><p id="Par13">Pancreatic ductal adenocarcinoma</p></def></def-item><def-item><term>RECIST</term><def><p id="Par14">Response Evaluation Criteria in Solid Tumors</p></def></def-item><def-item><term>RP2D</term><def><p id="Par15">Recommended phase 2 dose</p></def></def-item><def-item><term>SD</term><def><p id="Par16">Standard deviation</p></def></def-item><def-item><term>SMC</term><def><p id="Par17">Safety monitor committee</p></def></def-item><def-item><term>t<sub>1/2</sub></term><def><p id="Par18">Half-life of drug elimination</p></def></def-item><def-item><term>T<sub>max</sub></term><def><p id="Par19">Time to C<sub>max</sub></p></def></def-item><def-item><term>V<sub>z</sub></term><def><p id="Par20">Volume of distribution</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Qiang Xu, Xue Zhao and Xianze Wang contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the patients, their families, investigators, and the site staff. We would like to thank the following investigators from Peking Union Medical College Hospital: the trial team and pharmacological team from Phase I Unit of Clinical Pharmacology Research Centre, Huadan Xue and Liang Zhu for imaging efficacy evaluation, Ke Lv and Yunlu Feng for endoscopic ultrasound-guided puncture, and Huanwen Wu for pathological diagnosis. We thank Jun Zhang and Hao Geng from Hengrui for data collection, supervision, administration, and logistical support. Medical writing assistance was provided by Haofeng Ding (MS, medical writer at Hengrui) and Tengfei Zhang (PhD, medical writer at Hengrui) according to Good Publication Practice Guidelines.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>WW, XH, HW2 and QW conceived and designed this study. QX, XZ, XW1, RZ, YC, TX, HW1, HT, YS, MZ, CG, DF, XW2, TZ, XY1, YC, XC, ZL, RC, XH, and WW enrolled patients and collected the data. XY2 was responsible for directing the statistical analyses, and all authors participated in data interpretation. HW2, QW, XH, and WW had verified the data. Manuscript was drafted by XH and WW and was reviewed and/or revised by all authors. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data are available from the corresponding authors upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par50">The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol and all amendments were approved by the Ethics Committee of Peking Union Medical College Hospital (20211-EA1), Zhejiang Provincial People's Hospital (2021YW126), Union Hospital Tongji Medical College, Huazhong University of Science and Technology (2021&#x02013;0910), Shandong Cancer Hospital and Institute (SDZLEC2021-136&#x02013;01), The Second Affiliated Hospital of Anhui Medical University (YW2021-160), Tianjin Medical University Cancer Institute &#x00026; Hospital (E20210935), Huashan Hospital Fudan University (2021&#x02013;950), Harbin Medical University Cancer Hospital (2021&#x02013;224), The First Affiliated Hospital, Sun Yat-sen University (2021&#x02013;107), The Affiliated Cancer Hospital, Zhengzhou University (2021&#x02013;357-003), Sun Yat-sen Memorial Hospital, Sun Yat-sen University (2021-YW-099), and Guangdong Provincial People's Hospital (YW2021-101). All patients provided written informed consent.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par51">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par52">Xue Yang, Huan Wang, and Quanren Wang reports being employed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other disclosures are reported.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Hong</surname><given-names>TS</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name></person-group><article-title>Pancreatic adenocarcinoma</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>11</issue><fpage>1039</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1404198</pub-id><?supplied-pmid 25207767?><pub-id pub-id-type="pmid">25207767</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039&#x02013;49.<pub-id pub-id-type="pmid">25207767</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Fuchs</surname><given-names>HE</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2022</article-title><source>CA Cancer J Clin</source><year>2022</year><volume>72</volume><issue>1</issue><fpage>7</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.3322/caac.21708</pub-id><?supplied-pmid 35020204?><pub-id pub-id-type="pmid">35020204</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7&#x02013;33.<pub-id pub-id-type="pmid">35020204</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>W</given-names></name><name><surname>Chawla</surname><given-names>A</given-names></name><name><surname>O'Reilly</surname><given-names>EM</given-names></name></person-group><article-title>Pancreatic Cancer: A Review</article-title><source>JAMA</source><year>2021</year><volume>326</volume><issue>9</issue><fpage>851</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.13027</pub-id><?supplied-pmid 34547082?><pub-id pub-id-type="pmid">34547082</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Park W, Chawla A, O&#x02019;Reilly EM. Pancreatic Cancer: A Review. JAMA. 2021;326(9):851&#x02013;62.<pub-id pub-id-type="pmid">34547082</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Stathis</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name></person-group><article-title>Advanced pancreatic carcinoma: current treatment and future challenges</article-title><source>Nat Rev Clin Oncol</source><year>2010</year><volume>7</volume><issue>3</issue><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2009.236</pub-id><?supplied-pmid 20101258?><pub-id pub-id-type="pmid">20101258</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163&#x02013;72.<pub-id pub-id-type="pmid">20101258</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Mizrahi</surname><given-names>JD</given-names></name><name><surname>Surana</surname><given-names>R</given-names></name><name><surname>Valle</surname><given-names>JW</given-names></name><name><surname>Shroff</surname><given-names>RT</given-names></name></person-group><article-title>Pancreatic cancer</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10242</issue><fpage>2008</fpage><lpage>2020</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30974-0</pub-id><?supplied-pmid 32593337?><pub-id pub-id-type="pmid">32593337</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008&#x02013;20.<pub-id pub-id-type="pmid">32593337</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Desseigne</surname><given-names>F</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name><name><surname>Bouche</surname><given-names>O</given-names></name><name><surname>Guimbaud</surname><given-names>R</given-names></name><name><surname>Becouarn</surname><given-names>Y</given-names></name><etal/></person-group><article-title>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>19</issue><fpage>1817</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1011923</pub-id><?supplied-pmid 21561347?><pub-id pub-id-type="pmid">21561347</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817&#x02013;25.<pub-id pub-id-type="pmid">21561347</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version 2.2023. <ext-link ext-link-type="uri" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf">https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf</ext-link>. Accessed 31 Oct 2023.</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>De Dosso</surname><given-names>S</given-names></name><name><surname>Siebenhuner</surname><given-names>AR</given-names></name><name><surname>Winder</surname><given-names>T</given-names></name><name><surname>Meisel</surname><given-names>A</given-names></name><name><surname>Fritsch</surname><given-names>R</given-names></name><name><surname>Astaras</surname><given-names>C</given-names></name><etal/></person-group><article-title>Treatment landscape of metastatic pancreatic cancer</article-title><source>Cancer Treat Rev</source><year>2021</year><volume>96</volume><fpage>102180</fpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2021.102180</pub-id><?supplied-pmid 33812339?><pub-id pub-id-type="pmid">33812339</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">De Dosso S, Siebenhuner AR, Winder T, Meisel A, Fritsch R, Astaras C, et al. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev. 2021;96: 102180.<pub-id pub-id-type="pmid">33812339</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>de Man</surname><given-names>FM</given-names></name><name><surname>Goey</surname><given-names>AKL</given-names></name><name><surname>van Schaik</surname><given-names>RHN</given-names></name><name><surname>Mathijssen</surname><given-names>RHJ</given-names></name><name><surname>Bins</surname><given-names>S</given-names></name></person-group><article-title>Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics</article-title><source>Clin Pharmacokinet</source><year>2018</year><volume>57</volume><issue>10</issue><fpage>1229</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1007/s40262-018-0644-7</pub-id><?supplied-pmid 29520731?><pub-id pub-id-type="pmid">29520731</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229&#x02013;54.<pub-id pub-id-type="pmid">29520731</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Bailly</surname><given-names>C</given-names></name></person-group><article-title>Irinotecan: 25 years of cancer treatment</article-title><source>Pharmacol Res</source><year>2019</year><volume>148</volume><fpage>104398</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.104398</pub-id><?supplied-pmid 31415916?><pub-id pub-id-type="pmid">31415916</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148: 104398.<pub-id pub-id-type="pmid">31415916</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Kawato</surname><given-names>Y</given-names></name><name><surname>Aonuma</surname><given-names>M</given-names></name><name><surname>Hirota</surname><given-names>Y</given-names></name><name><surname>Kuga</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name></person-group><article-title>Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><issue>16</issue><fpage>4187</fpage><lpage>4191</lpage><?supplied-pmid 1651156?><pub-id pub-id-type="pmid">1651156</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51(16):4187&#x02013;91.<pub-id pub-id-type="pmid">1651156</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Milano</surname><given-names>G</given-names></name><name><surname>Innocenti</surname><given-names>F</given-names></name><name><surname>Minami</surname><given-names>H</given-names></name></person-group><article-title>Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs</article-title><source>Cancer Sci</source><year>2022</year><volume>113</volume><issue>7</issue><fpage>2224</fpage><lpage>2231</lpage><pub-id pub-id-type="doi">10.1111/cas.15377</pub-id><?supplied-pmid 35445479?><pub-id pub-id-type="pmid">35445479</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Milano G, Innocenti F, Minami H. Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs. Cancer Sci. 2022;113(7):2224&#x02013;31.<pub-id pub-id-type="pmid">35445479</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>YN</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name></person-group><article-title>Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma</article-title><source>Drugs</source><year>2017</year><volume>77</volume><issue>7</issue><fpage>785</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1007/s40265-017-0741-1</pub-id><?supplied-pmid 28401446?><pub-id pub-id-type="pmid">28401446</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Lamb YN, Scott LJ. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. Drugs. 2017;77(7):785&#x02013;92.<pub-id pub-id-type="pmid">28401446</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Frampton</surname><given-names>JE</given-names></name></person-group><article-title>Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma</article-title><source>Drugs</source><year>2020</year><volume>80</volume><issue>10</issue><fpage>1007</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1007/s40265-020-01336-6</pub-id><?supplied-pmid 32557396?><pub-id pub-id-type="pmid">32557396</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Frampton JE. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. Drugs. 2020;80(10):1007&#x02013;18.<pub-id pub-id-type="pmid">32557396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">US Food and Drug Administration. Prescribing information for ONIVYDE. 2023. <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207793s015lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207793s015lbl.pdf</ext-link>. Accessed 13 Nov 2023.</mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang-Gillam</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>CP</given-names></name><name><surname>Bodoky</surname><given-names>G</given-names></name><name><surname>Dean</surname><given-names>A</given-names></name><name><surname>Shan</surname><given-names>YS</given-names></name><name><surname>Jameson</surname><given-names>G</given-names></name><etal/></person-group><article-title>Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial</article-title><source>Lancet</source><year>2016</year><volume>387</volume><issue>10018</issue><fpage>545</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00986-1</pub-id><?supplied-pmid 26615328?><pub-id pub-id-type="pmid">26615328</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545&#x02013;57.<pub-id pub-id-type="pmid">26615328</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Wainberg</surname><given-names>ZA</given-names></name><name><surname>Melisi</surname><given-names>D</given-names></name><name><surname>Macarulla</surname><given-names>T</given-names></name><name><surname>Pazo Cid</surname><given-names>R</given-names></name><name><surname>Chandana</surname><given-names>SR</given-names></name><name><surname>De La Fouchardi&#x000e8;re</surname><given-names>C</given-names></name><etal/></person-group><article-title>NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial</article-title><source>Lancet</source><year>2023</year><volume>402</volume><issue>10409</issue><fpage>1272</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)01366-1</pub-id><?supplied-pmid 37708904?><pub-id pub-id-type="pmid">37708904</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardi&#x000e8;re C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272&#x02013;81.<pub-id pub-id-type="pmid">37708904</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Rommasi</surname><given-names>F</given-names></name><name><surname>Esfandiari</surname><given-names>N</given-names></name></person-group><article-title>Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy</article-title><source>Nanoscale Res Lett</source><year>2021</year><volume>16</volume><issue>1</issue><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s11671-021-03553-8</pub-id><?supplied-pmid 34032937?><pub-id pub-id-type="pmid">34032937</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Rommasi F, Esfandiari N. Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy. Nanoscale Res Lett. 2021;16(1):95.<pub-id pub-id-type="pmid">34032937</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>D'Souza</surname><given-names>AA</given-names></name><name><surname>Shegokar</surname><given-names>R</given-names></name></person-group><article-title>Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications</article-title><source>Expert Opin Drug Deliv</source><year>2016</year><volume>13</volume><issue>9</issue><fpage>1257</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1080/17425247.2016.1182485</pub-id><?supplied-pmid 27116988?><pub-id pub-id-type="pmid">27116988</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">D&#x02019;Souza AA, Shegokar R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv. 2016;13(9):1257&#x02013;75.<pub-id pub-id-type="pmid">27116988</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Litzinger</surname><given-names>DC</given-names></name><name><surname>Buiting</surname><given-names>AM</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes</article-title><source>Biochim Biophys Acta</source><year>1994</year><volume>1190</volume><issue>1</issue><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(94)90038-8</pub-id><?supplied-pmid 8110825?><pub-id pub-id-type="pmid">8110825</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Litzinger DC, Buiting AM, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta. 1994;1190(1):99&#x02013;107.<pub-id pub-id-type="pmid">8110825</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Danaei</surname><given-names>M</given-names></name><name><surname>Dehghankhold</surname><given-names>M</given-names></name><name><surname>Ataei</surname><given-names>S</given-names></name><name><surname>Hasanzadeh Davarani</surname><given-names>F</given-names></name><name><surname>Javanmard</surname><given-names>R</given-names></name><name><surname>Dokhani</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems</article-title><source>Pharmaceutics</source><year>2018</year><volume>10</volume><issue>2</issue><fpage>57</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics10020057</pub-id><?supplied-pmid 29783687?><pub-id pub-id-type="pmid">29783687</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018;10(2):57.<pub-id pub-id-type="pmid">29783687</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Peer</surname><given-names>D</given-names></name><name><surname>Karp</surname><given-names>JM</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Farokhzad</surname><given-names>OC</given-names></name><name><surname>Margalit</surname><given-names>R</given-names></name><name><surname>Langer</surname><given-names>R</given-names></name></person-group><article-title>Nanocarriers as an emerging platform for cancer therapy</article-title><source>Nat Nanotechnol</source><year>2007</year><volume>2</volume><issue>12</issue><fpage>751</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1038/nnano.2007.387</pub-id><?supplied-pmid 18654426?><pub-id pub-id-type="pmid">18654426</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751&#x02013;60.<pub-id pub-id-type="pmid">18654426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>LBA61 HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)</article-title><source>Ann Oncol</source><year>2022</year><volume>33</volume><fpage>S1426</fpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.08.063</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Wang L, Qin S, Zhou Y, Zhang S, Sun X, Chen Z, et al. LBA61 HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC). Ann Oncol. 2022;33:S1426.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Wainberg</surname><given-names>ZA</given-names></name><name><surname>Bekaii-Saab</surname><given-names>T</given-names></name><name><surname>Boland</surname><given-names>PM</given-names></name><name><surname>Dayyani</surname><given-names>F</given-names></name><name><surname>Macarulla</surname><given-names>T</given-names></name><name><surname>Mody</surname><given-names>K</given-names></name><etal/></person-group><article-title>First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study</article-title><source>Eur J Cancer</source><year>2021</year><volume>151</volume><fpage>14</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2021.03.028</pub-id><?supplied-pmid 33957442?><pub-id pub-id-type="pmid">33957442</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, et al. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Eur J Cancer. 2021;151:14&#x02013;24.<pub-id pub-id-type="pmid">33957442</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Chabot</surname><given-names>GG</given-names></name></person-group><article-title>Clinical pharmacokinetics of irinotecan</article-title><source>Clin Pharmacokinet</source><year>1997</year><volume>33</volume><issue>4</issue><fpage>245</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.2165/00003088-199733040-00001</pub-id><?supplied-pmid 9342501?><pub-id pub-id-type="pmid">9342501</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997;33(4):245&#x02013;59.<pub-id pub-id-type="pmid">9342501</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">US Food and Drug Administration. Prescribing information for CAMPTOSAR. 2022. <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020571Orig1s053lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020571Orig1s053lbl.pdf</ext-link>. Accessed 13 Nov 2023.</mixed-citation></ref></ref-list></back></article>